Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma

Malignant pheochromocytoma/paraganglioma (PCC/PGL) is defined by the presence of metastases at non-chromaffin sites, which makes it difficult to prospectively diagnose malignancy. Here, we performed array CGH (aCGH) and paired gene expression profiling of fresh, frozen PCC/PGL samples (n = 12), including three malignant tumors, to identify genes that distinguish benign from malignant tumors. Most PCC/PGL cases showed few copy number aberrations, regardless of malignancy status, but mRNA analysis revealed that 390 genes were differentially expressed in benign and malignant tumors. Expression of the enzyme, phenylethanolamine N-methyltransferase (PNMT), which catalyzes the methylation of norepinephrine to epinephrine, was significantly lower in malignant PCC/PGL as compared to benign samples. In 62 additional samples, we confirmed that PNMT mRNA and protein levels were decreased in malignant PCC/PGL using quantitative real-time polymerase chain reaction and immunohistochemistry. The present study demonstrates that PNMT downregulation correlates with malignancy in PCC/PGL and identifies PNMT as one of the most differentially expressed genes between malignant and benign tumors.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.8234PMID 27007161PMCID 5029690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WHO classification of tumours of endocrine organs

  2017cited by this paper
• Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity

  2014cited by this paper
• Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.

  2014cited by this paper
• Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.

  2012cited by this paper
• Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.

  2011cited by this paper
• Pheochromocytomas and paragangliomas: assessment of malignant potential

  2011cited by this paper
• Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.

  2010cited by this paper
• Germline mutations in TMEM127 confer susceptibility to pheochromocytoma

  2010cited by this paper
• Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score

  2009cited by this paper
• Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

  2008cited by this paper
• Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.

  2007cited by this paper
• Clinical analysis of malignant pheochromocytoma

  2006cited by this paper
• International Agency for Research on Cancer (IARC)

  2006cited by this paper
• Gene Expression Profiling of Benign and Malignant Pheochromocytoma

  2006cited by this paper
• Identification of phenylethanolamine N‐methyltransferase gene expression in stellate ganglia and its modulation by stress

  2006cited by this paper
• A HIF1-alpha Regulatory Loop Links Hypoxiaand Mitochondrial Signals in Pheochromocytomas

  2005cited by this paper
• A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas

  2005cited by this paper
• Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome.

  2004cited by this paper
• Malignant pheochromocytoma: current status and initiatives for future progress.

  2004cited by this paper
• KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and Paraganglioma

  2003cited by this paper
• A comparative immunohistochemical study of spontaneous and chemically induced pheochromocytomas in B6C3F1 mice

  2003influential reference
• Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

  2003cited by this paper
• HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma

  2003cited by this paper
• Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases

  2002cited by this paper
• The value of plasma markers for the clinical behaviour of phaeochromocytomas.

  2002cited by this paper
• Stress increases gene expression of phenylethanolamine N-methyltransferase in spleen of rats via pituitary-adrenocortical mechanism.

  2002cited by this paper
• N-cadherin expression in adrenal tumors: Upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma

  2002cited by this paper
• Phenylethanolamine N-methyl transferase expression in mouse thymus and spleen.

  2002cited by this paper
• Increased Expression of Tenascin in Pheochromocytomas Correlates With Malignancy

  2001cited by this paper
• Stress-triggered activation of gene expression in catecholaminergic systems: dynamics of transcriptional events.

  2001cited by this paper
• Existence of cardiac PNMT mRNA in adult rats: elevation by stress in a glucocorticoid-dependent manner.

  2001cited by this paper
• Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.

  2001cited by this paper
• Ontogeny of epinephrine metabolic pathways in the rat: role of glucocorticoids

  2000cited by this paper
• Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas.

  2000cited by this paper
• Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology.

  2000cited by this paper
• Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas.

  1998cited by this paper
• Phenylethanolamine N-methyltransferase mRNA in rat spleen and thymus.

  1998cited by this paper
• Expression of phenylethanolamine n-methyltransferase in the embryonic rat heart.

  1996cited by this paper
• Nonadrenal epinephrine-forming enzymes in humans. Characteristics, distribution, regulation, and relationship to epinephrine levels.

  1995cited by this paper
• Discrepancy between PNMT presence and relative lack of adrenaline production in extra‐adrenal pheochromocytoma

  1994cited by this paper
• Genetic linkage of the human gene for phenylethanolamine N-methyltransferase (PNMT), the adrenaline-synthesizing enzyme, to DNA markers on chromosome 17q21-q22.

  1992cited by this paper
• Adrenal Phenylethanolamine N‐Methyltransferase Induction in Relation to Glucocorticoid Receptor Dynamics: Evidence that Acute Exposure to High Cortisol Levels Is Sufficient to Induce the Enzyme

  1992cited by this paper
• The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma

  1992cited by this paper
• Immunohistochemical localization of epinephrine, norepinephrine, catecholamine-synthesizing enzymes, and chromogranin in neuroendocrine cells and tumors.

  1986cited by this paper
• Catecholamine-synthesizing enzymes in paraganglia of aged Fischer-344 rats

  1984cited by this paper
• Studies on the distribution of phenylethanolamine N-methyltransferase and epinephrine in the rat.

  1978cited by this paper
• Purification and properties of phenylethanolamine-N-methyl transferase.

  1962cited by this paper
• The formation of adrenaline from noradrenaline.

  1957cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes

  year unknowncited by this paper

• Intracystic catecholamine variations in cystic pheochromocytoma

  2025cites this paper
• Tumor metabolism in pheochromocytomas: clinical and therapeutic implications

  2024cites this paper
• Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice.

  2024cites this paper
• HIF2α regulates the synthesis and release of epinephrine in the adrenal medulla

  2021cites this paper
• What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

  2021cites this paper
• Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas

  2021cites this paper
• Hypoxia pathway proteins regulate the synthesis and release of epinephrine in the mouse adrenal gland

  2020cites this paper
• Preoperative risk factors for massive blood loss in adrenalectomy for pheochromocytoma

  2017cites this paper
• Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience

  2016cites this paper
• Urology pertinent neuroendocrine tumors: focusing on renal pelvis, bladder, prostate located sympathetic functional paragangliomas.

  2016cites this paper